USA flag logo/image

An Official Website of the United States Government

LASERS IN THE TREATMENT OF HEART DISEASE IN NEONATES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
39494
Program Year/Program:
1997 / SBIR
Agency Tracking Number:
39494
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CONVERSION ENERGY ENTERPRISES
81 PINE BROOK RD SPRING VALLEY, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1997
Title: LASERS IN THE TREATMENT OF HEART DISEASE IN NEONATES
Agency: HHS
Contract: HL59062-01
Award Amount: $97,590.00
 

Abstract:

DESCRIPTION (Adapted from applicant's abstract): Increasingly complex neonatal cardiac repairs are being performed on younger and younger infants with greater success. Yet as treatment runs closer to what is tolerable to the body, smaller details become major determinants of success. Two outstanding independent variables are associated with poorer outcome; excess hemorrhage and prolonged operative time, particularly cardiopulmonary bypass time. Excess hemorrhage requires excess blood transfusion with the risks of infectious agent transmittal and hemostatic and metabolic insult to the neonate. Long bypass times produce more pronounced inflammatory responses by the host with secondary organ dysfunction. The ability to minimize these factors will increase the safety of the operation and will significantly reduce expenses such as ICU, hospital stays and blood product costs. Recent advances in laser technology may provide this improvement in hemostasis and thereby reduce the operation time. This project will study the impact of laser activated hemostatic methods on conventional anastomotic techniques as well as laser welding methods developed previously by the research team. Phase I will include both in vitro and in vivo experiments. Spectroscopic measurements on neonatal tissue will guide the selection of the laser wavelength. Both temperature and optical feedback techniques developed under the CEE/LLNL CRADA will be used for controlling the laser to promote strong tissue bonds. Tissue solders or patches will be evaluated to enhance tissue welding and hemostasis. Phase II will focus on sensor control of the laser and will be based on neonatal tissue signature change at the welding endpoint. The subsequent development of a reliable tissue welding system will provide the bond strength and the ability to grow rapidly as required in the neonate. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 444 --PROJECT NUMBER......1 R43 HL59067-01 INVESTIGATOR NAME/ADDRESS FY 97 HIGGINS, GERALD A IRG/INTRAMURAL UNIT..ZRG7 CIEMED GLOBAL ENTERPRISES AWARD AMOUNT......... $99,695 1919 GALLOWS RD 10TH FLOOR VIENNA, VA 22182 PERFORMING ORGANIZATION: IMAGE MEDICAL COMMUNICATIONS TITLE VIRTUAL REALITY BASED ANGIOPLASTY SIMULATOR ABSTRACT: DESCRIPTION (Adapted from applicant's abstract): The applicants propose to develop a virtual reality-based simulator for interventional cardiology. The goal of this work is to simulate the "look and feel" of diagnostic catheterization, percutaneous transluminal coronary angioplasty (PTCA), and coronary stenting with enough accuracy to serve as a platform for the design and evaluation of cardiovascular devices. Emphasis will be placed on validation of the simulator as a teaching and certification instrument for physician training and accreditation. The simulator will be based on the da Vinci catheter insertion simulator for interventional radiology developed at the Centre for Information-enhanced Medicine of the Johns Hopkins University School of Medicine. The simulator will be configured using finite element modeling to provide accurate physical applications of devices such as catheters, guidewires, dilatation balloons and stents. Models of the heart and the treat vessels will be derived from the Visible Human Project and patient-specific data. The development of a high fidelity interventional cardiology simulator will lead to a reduction in health care costs by reducing medical device errors, improving physician performance by reducing the learning curves in which human patients are used, reduce training on patients and animals, and providing a mechanism for maintenance of physician competence. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 445 --PROJECT NUMBER......1 R43 HL59071-01 INVESTIGATOR NAME/ADDRESS FY 97 DHAWALE, PARITOSH J IRG/INTRAMURAL UNIT..ZRG7 TECHNOLOGY SOLUTIONS GROUP LTD AWARD AMOUNT......... $99,797 6685 BETA DR SUITE 2 MAYFIELD VILLAGE, OH 44143 PERFORMING ORGANIZATION: TECHNOLOGY SOLUTIONS GROUP, LTD TITLE QUANTITATIVE VOLUMETRIC INTRAVASCULAR ULTRASOUND ABSTRACT: Accurate volumetric quantification of atherosclerotic disease is critical in a number of clinical situations. We propose to develop and validate three-dimensional intravascular ultrasound methodology to quantify changes in volumetric distribution of atherosclerotic disease. In the Phase-I of this project new image processing algorithms will be developed to more accurately detect complex lumen borders. Realistic experiments will be designed to test the fundamental assumption that the displacement of the imaging device inside the artery is well represented by the displacement measured outside the body. Phantoms with known shapes will be constructed and volumetric analysis will be performed to determine accuracy and reproducibility. In the Phase-II of this project, we will enhance the software features with database support, angiographic visualization and tissue characterization. Rigorous in-vivo studies will also be performed to develop the methodology as a validated clinical tool. The product will not only have clinical application in evaluating interventional procedures, but will also be an effective tool for monitoring regression and restenosis.

Principal Investigator:

Soltz, barbara a
0

Business Contact:


9144259170
Small Business Information at Submission:

Conversion Energy Enterprises
81 PINE BROOK RD Spring Valley, NY 10977

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No